Expanding the discovery of small molecules, AstraZeneca reached a new drug development cooperation
January 19, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, X-Chem, a biotechnology company focused on small molecule discovery, announced that it will further expand its cooperation with AstraZeneca on global drug discovery projects. The new agreement focuses on the synthesis and delivery of AstraZeneca's custom libraries, as well as the transfer of the DEX platform, allowing AstraZeneca to screen DNA-encoded libraries. This is the third agreement between AstraZeneca and X-Chem since 2012. Through previous collaborations, both parties have discovered new small molecules licensed for transfer in multiple drug discovery programs and indications.
Under the terms of the agreement, X-Chem will receive prior technical access and licensing fees, as well as several years of funding commitments. X-Chem is also expected to receive implementation fees for specific technology transfer programs, as well as additional payments related to certain R&D and commercial milestones. In addition, X-Chem is eligible for a patent tax for drugs that have been successfully commercialized through a targeted collaborative project.
X-Chem's DEX Drug Discovery Engine is based on a library of DNA-encoded libraries containing more than 120 billion independent small molecule compounds derived from an iterative combinatorial chemistry where each compound's label is recorded in a DNA barcode. Using this library, low-throughput, affinity screening of biological targets can be performed, and "fishing" ligands are identified by DNA sequencing. The innovations of the DEX platform are library design, screening methods, and bioinformatics. These innovations have enabled X-Chem to successfully overcome the difficulties of conventional screening failures, and have discovered more than 100 fragments, low molecular weight heterocycles, macrocycles, and irreversible covalently electrophilic lead compounds, all of which are licensed to partners.
â–² Dr. Menelas Pangalos, Executive Vice President, Innovation and Biodiversity Technology, AstraZeneca (Source: AstraZeneca Official Website)
Dr. Menelas Pangalos, Executive Vice President of AstraZeneca's Innovative Medicines and Early Development Biotechnology Division, said: "The DEX platform is an important pillar of our small molecule discovery strategy. Based on the success of the cooperation with X-Chem over the past five years, we have achieved long-term technical aspects. The consensus of cooperation."
â–² Dr. Rick Wagner, CEO of X-Chem (Source: X-Chem Official Website)
Dr. Rick Wagner, CEO of X-Chem, said: "The partnership with AstraZeneca is one of X-Chem's longest and most fruitful collaborations. AstraZeneca decided to internalize the DEX platform and conduct DEL screening internally. Demonstrate the power of DEX technology and its importance for the discovery of small molecule drugs in the future."
Reference materials:
[1] X-Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with AstraZeneca
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bio-pharmacies.com